Correlation of early-phase β-amyloid positron-emission-tomography and neuropsychological testing in patients with Alzheimer’s disease

Völter, Friederike ; Eckenweber, Sebastian; Scheifele, Maximilian; Eckenweber, Florian; Hirsch, Fabian; Franzmeier, Nicolai ; Kreuzer, Annika; Griessl, Maria; Steward, Anna ; Janowitz, Daniel ; Palleis, Carla ; Bernhardt, Alexander ; Vöglein, Jonathan ; Stockbauer, Anna; Rauchmann, Boris-Stephan ; Schöberl, Florian; Wlasich, Elisabeth; Buerger, Katharina ; Wagemann, Olivia; Perneczky, Robert ; Weidinger, Endy; Höglinger, Günter ; Levin, Johannes ; Brendel, Matthias und Schönecker, Sonja (2025): Correlation of early-phase β-amyloid positron-emission-tomography and neuropsychological testing in patients with Alzheimer’s disease. In: European Journal of Nuclear Medicine and Molecular Imaging [Forthcoming]

Abstract

Purpose : Clinical staging in individuals with Alzheimer’s disease (AD) typically relies on neuropsychological testing. Recognizing the imperative for an objective measure of clinical AD staging, regional perfusion in early-phase β-amyloid-PET may aid as a cost-efficient index for the assessment of neurodegeneration severity in patients with Alzheimer’s disease.

Methods : Regional perfusion deficits in early-phase β-amyloid-PET as well as neuropsychological testing (max. 90 days delay) were evaluated in 82 patients with biologically defined AD according to the ATN classification. In reference to the Braak staging system patients were classified into the groups stage0, stageI−II+, stageI−IV+, stageI−VI+, and stageatypical+ according to regional perfusion deficits in regions of interest (ROIs) published by the Alzheimer’s Disease Neuroimaging Initiative. Multiple regression analysis controlling for age, gender, and education was used to evaluate the association of regional z-scores on perfusion-phase PET with clinical scores for all patients and with annual decline of cognitive performance in 23 patients with follow-up data.

Results : Patients classified as stage0 and stageI−II+ demonstrated significantly superior neuropsychological performance compared to those classified as stageI−IV+ and stageI−VI+. Lower cognitive performance was associated with decreased perfusion in early-phase β-amyloid-PET globally and regionally, with the most pronounced association identified in the left temporal lobe. Mean z-scores on early-phase PET in temporal and parietal regions offered a robust prediction of future annual decline in MMSE and sum scores of the CERAD-Plus (Consortium to Establish a Registry for Alzheimer’s Disease) test battery.

Conclusion : Regional and global perfusion deficits in early-phase β-amyloid-PET can serve as an objective index of neurodegeneration severity and may act as prognostic markers of future cognitive decline in AD.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin > Munich Cluster for Systems Neurology (SyNergy) ; Medizin > Institut für Schlaganfall- und Demenzforschung (ISD) ; Medizin > Klinikum der LMU München ; Medizin > Klinikum der LMU München > Medizinische Klinik und Poliklinik IV (Endokrinologie, Nephrologie, weitere Sektionen) ; Medizin > Klinikum der LMU München > Neurologische Klinik und Poliklinik mit Friedrich-Baur-Institut ; Medizin > Klinikum der LMU München > Klinik und Poliklinik für Nuklearmedizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 1619-7070
• Sprache: Englisch
• DFG: Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198